• English
  • Korean
  • Chinese
表紙
市場調査レポート - 244298

Namenda(アルツハイマー病治療薬):市場の予測と分析

Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

発行 GlobalData
出版日 ページ情報 英文 62 Pages
価格
Namenda(アルツハイマー病治療薬):市場の予測と分析 Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022
出版日: 2013年07月31日 ページ情報: 英文 62 Pages
概要

Namenda(メマンチン塩酸塩)はアルツハイマー病(AD)の第一級の治療薬で、現在利用可能な薬剤と比べて独特の機能メカニズム(MOA)を有しています。この薬剤は経口活性NMDA型受容体で、中〜重度のアルツハイマー性痴呆症の治療薬として認可された、世界初の(当時は唯一の)治療薬となっています。

当レポートでは、アルツハイマー病(AD)の治療薬の一つ、Namenda(ナメンダ)の世界市場について分析し、アルツハイマー病の概要や治療法、競合する企業・薬品の概要、アンメットニーズと市場機会、Ariceptの商品情報(特色・効能・安全性など)、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 分析背景
  • 関連調査

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態
  • 兆候

第4章 疾患の管理

  • 診断
    • Probable AD(アルツハイマー病の可能性の高い)型認知症
    • Possible AD(アルツハイマー病の可能性がある)型認知症
    • ADの病態生理学的な過程の証拠がある、Probable AD型痴呆症
    • ADの病態生理学的な過程の証拠がある、Possible AD型痴呆症
    • 前臨床AD
    • 軽度認知障害
  • 治療の概要

第5章 競争環境

  • 概要
  • 競合企業の戦略的評価

第6章 Namenda(塩酸メマンチン)について

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData has released its new PharmaPoint Drug Evaluation report, "Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Namenda (memantine hydrochloride) is a first-in-class medication for AD with a unique MOA compared with the currently available drugs. It is an orally-active NMDA receptor antagonist and was the first, and at the time, the only, medication approved for the treatment of moderate to severe dementia of the Alzheimer's type.

Scope

  • Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Namenda including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Namenda for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for AD
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Namenda performance
  • Obtain sales forecast for Namenda from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)

Table of Contents

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 7
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Catalyst 8
  • 2.2 Related Reports 9

3 Disease Overview 11

  • 3.1 Etiology and Pathophysiology 12
    • 3.1.1 Etiology 12
    • 3.1.2 Pathophysiology 15
  • 3.2 Symptoms 27

4 Disease Management 29

  • 4.1 Diagnosis 29
    • 4.1.1 Probable Alzheimer's Disease Dementia 30
    • 4.1.2 Possible AD Dementia 31
    • 4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 31
    • 4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 32
    • 4.1.5 Preclinical AD 32
    • 4.1.6 Mild Cognitive Impairment 33
  • 4.2 Treatment Overview 35

5 Competitive Assessment 38

  • 5.1 Overview 38
  • 5.2 Strategic Competitor Assessment 38

6 Namenda (memantine hydrochloride) 41

  • 6.1 Overview 41
  • 6.2 Efficacy 42
  • 6.3 Safety 43

6.4 SWOT Analysis 44

  • 6.5 Forecast 44

7 Appendix 46

  • 7.1 Bibliography 46
  • 7.2 Abbreviations 50
  • 7.3 Methodology 53
  • 7.4 Forecasting Methodology 53
    • 7.4.1 Diagnosed AD patients 54
    • 7.4.2 Percent Drug-treated Patients 55
    • 7.4.3 General Pricing Assumptions 55
    • 7.4.4 Individual Drug Assumptions 57
    • 7.4.5 Generic Erosion 57
  • 7.5 Physicians and Specialists Included in this Study 58
  • 7.6 About the Authors 59
    • 7.6.1 Author 59
    • 7.6.2 Global Head of Healthcare 60
  • 7.7 About GlobalData 61
  • 7.8 Disclaimer 61

List of Tables

1.1 List of Tables

  • Table 1: Symptoms of AD 28
  • Table 2: Guidelines for the Treatment of AD 35
  • Table 3: Most Prescribed Drugs for AD by Class in the Global Markets, 2012 36
  • Table 4: Leading Branded Treatments for AD, 2013 39
  • Table 5: Product Profile- Namenda 42
  • Table 6: Namenda SWOT Analysis, 2013 44
  • Table 7: Global Sales Forecasts ($m) for Namenda, 2012-2022 45

List of Figures

1.2 List of Figures

  • Figure 1: Atrophy of the Brain in AD 17
  • Figure 2: Key Pathological Features in AD Versus a Healthy Neuron 19
  • Figure 3: Non-Amyloidogenic Metabolism of APP 21
  • Figure 4: Amyloidogenic Metabolism of APP 22
  • Figure 5: Neurofibrillary Tangles 24
  • Figure 6: Oxidative Damage Due to Free Radicals 26
  • Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013 40
Back to Top